Talfirastide
 | It has been suggested that this article be merged into Angiotensin (1-7). (Discuss) Proposed since December 2023. |
Talfirastide (development name TXA127) is an experimental synthetic analog of angiotensin (1-7)[1] that works as an angiotensin II type 1 receptor–biased ligand. It has been tested in people with COVID-19[2] and stroke.[3]
References[edit]
- ^ Wagener, Gebhard; Goldklang, Monica P.; et al. (28 July 2022). "A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19". Critical Care. 26 (1): 229. doi:10.1186/s13054-022-04096-9. ISSN 1364-8535. PMC 9332096. PMID 35902867.
- ^ Self, Wesley H.; Shotwell, Matthew S.; et al. (11 April 2023). "Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials". JAMA. 329 (14): 1170–1182. doi:10.1001/jama.2023.3546. PMC 10091180. PMID 37039791. S2CID 258062415.
- ^ "Phase 2 Study of TXA127 in Post-ischemic Stroke Patients - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 7 December 2023.